Prospective evaluation of fexapotide triflutate injection treatment of Grade Group 1 prostate cancer: 4-year results

por Shore, Neal, Kaplan, Steven A., Tutrone, Ronald, Levin, Richard, Bailen, James, Hay, Alan, Kalota, Susan, Bidair, Mohamed, Freedman, Sheldon, Goldberg, Kenneth, Snoy, Frederick, Epstein, Jonathan I.
Publicado 2020

Wound Healing Is Accelerated by Agonists of Adenosine A(2) (G(α) (s)-linked) Receptors

por Montesinos, M. Carmen, Gadangi, Pratap, Longaker, Michael, Sung, Joanne, Levine, Jamie, Nilsen, Diana, Reibman, Joan, Li, Min, Jiang, Chuan-Kui, Hirschhorn, Rochelle, Recht, Phoebe A., Ostad, Edward, Levin, Richard I., Cronstein, Bruce N.
Publicado 1997

Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement

por Shore, Neal, Tutrone, Ronald, Efros, Mitchell, Bidair, Mohamed, Wachs, Barton, Kalota, Susan, Freedman, Sheldon, Bailen, James, Levin, Richard, Richardson, Stephen, Kaminetsky, Jed, Snyder, Jeffrey, Shepard, Barry, Goldberg, Kenneth, Hay, Alan, Gange, Steven, Grunberger, Ivan
Publicado 2018

Indirect effects of the COVID-19 pandemic on paediatric healthcare use and severe disease: a retrospective national cohort study

por Williams, Thomas C, MacRae, Clare, Swann, Olivia V, Haseeb, Haris, Cunningham, Steve, Davies, Philip, Gibson, Neil, Lamb, Christopher, Levin, Richard, McDougall, Catherine M, McFadzean, Jillian, Piper, Ian, Turner, Alastair, Turner, Stephen W, Van Dijke, Margrethe, Urquhart, Donald S, Guthrie, Bruce, Langley, Ross J
Publicado 2021